Thromboxanes

Physiologically active compounds found in many organs of the body. They are formed in vivo from the prostaglandin endoperoxides and cause platelet aggregation, contraction of arteries, and other biological effects. Thromboxanes are important mediators of the actions of polyunsaturated fatty acids transformed by cyclooxygenase.

Also Known As:

Networked: 2439 relevant articles (77 outcomes, 255 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Davì, Giovanni: 22 articles (11/2016 - 07/2003)
2.	Santilli, Francesca: 16 articles (01/2020 - 07/2003)
3.	Patrono, Carlo: 12 articles (01/2022 - 07/2003)
4.	Dogné, Jean-Michel: 12 articles (01/2016 - 01/2002)
5.	Rocca, Bianca: 10 articles (01/2022 - 02/2004)
6.	Liani, Rossella: 10 articles (01/2020 - 01/2011)
7.	Patrignani, Paola: 9 articles (01/2022 - 01/2003)
8.	Lattanzio, Stefano: 9 articles (09/2016 - 08/2008)
9.	Kinsella, B Therese: 8 articles (04/2020 - 06/2006)
10.	Violi, Francesco: 8 articles (01/2018 - 03/2005)

Related Diseases

1.	Thrombosis (Thrombus) 10/01/2000 - "We have shown previously that fresh garlic extract is effective in reducing thromboxane formation by platelets both in vivo and in vitro animal models of thrombosis. " 04/01/2000 - "The use of fresh aqueous garlic extract is known to be effective in reducing thromboxane formation by platelets in both in vivo and in vitro animal models of thrombosis. " 01/29/2012 - "Thrombocyte aggregation inhibitors were examined in number of studies because they reduced thromboxane mediated vasoconstriction and inhibited placental thrombosis. " 03/01/1999 - "In the present study we prospectively investigated whether an increase in platelet thromboxane formation actually precedes arterial microvascular thrombosis. " 01/01/2018 - "PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway: comment."
2.	Pulmonary Hypertension 11/01/2009 - "Strong activation of thromboxane synthesis is assumed to correlate with severe pulmonary hypertension. " 06/01/2009 - "Thromboxane A(2) and endothelial dysfunction are implicated in the development of pulmonary hypertension. " 08/01/2002 - "Pulmonary hypertension being elicited by infusion of the thromboxane A(2) analog, 9,11-epithio-11,12-methano-thromboxane A(2) (ONO-11113) was instead not amenable to ET(A)R inhibition. " 01/01/1996 - "Anoxic ischemic-perfused lungs had decreased pulmonary hypertension and thromboxane release, but sigma alb and Kf were not altered. " 07/01/1995 - "The relationship between Ppc and lymph flow was first determined by increasing Ppc by left atrial balloon inflation, and was then used to determine Ppc during pulmonary hypertension produced by infusion of a thromboxane analog. "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 08/01/1995 - "Thromboxane contributes to submaximal coronary dilation during myocardial ischemia." 12/01/1990 - "Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries." 01/01/1985 - "Platelet activation, with the subsequent generation of Thromboxane (Tx) A2, has been implied as a possible cause of resting as well as exercise induced myocardial ischemia. " 08/01/1982 - "Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease." 07/09/1981 - "Thromboxane in ischemic heart disease."
4.	Asthma (Bronchial Asthma) 01/01/2002 - "Large scale clinical trials are necessary to further define the role of thromboxane modulators in the treatment of patients with asthma." 08/08/2003 - "Thromboxane A(2) has been implicated as a mediator of bronchial hyperresponsiveness in asthma. " 02/01/2002 - "Therapeutic potential of thromboxane inhibitors in asthma." 01/01/2002 - "Thromboxane A(2) is believed to be involved not only in late asthmatic responses but also in bronchial hyperresponsiveness, a typical feature of asthma. " 01/01/2002 - "Among these mediators, thromboxane A(2) (TXA(2)) has attracted attention as an important mediator in the pathophysiology of asthma because of its potent bronchoconstrictive activity. "
5.	Hemorrhage 04/13/2001 - "Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding." 01/01/2021 - "One patient was found to have a rare genetic defect in thromboxane synthesis with associated markedly impaired platelet aggregation, while no obvious cause of the bleeding was found in the second patient. " 03/01/1995 - "These drugs produce a systemic bleeding tendency by impairing thromboxane-dependent platelet aggregation and consequently prolonging the bleeding time. " 04/01/1994 - "A broken mucosa and inhibition of thromboxane synthesis both appear to be necessary for bleeding to occur. " 10/01/1990 - "Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds."

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Aspirin (Acetylsalicylic Acid)
3.	Leukotrienes
4.	Thromboxane Receptors (Thromboxane Receptor)
5.	Prostaglandins
6.	ozagrel
7.	Thromboxane A2 (A2, Thromboxane)
8.	Thromboxane-A Synthase
9.	Eicosanoids
10.	Acids

Related Therapies and Procedures

1.	Therapeutics
2.	Self-Help Devices (Assistive Technology)
3.	Secondary Prevention
4.	Intravenous Infusions
5.	Cardiopulmonary Bypass (Heart-Lung Bypass)